Expired
Lead Plaintiff Deadline
Jun 3, 2025
Choose your preferred way to stay informed of new case launches and settlement deadlines
According to the complaint, Cerevel’s October 16, 2023 secondary stock offering (the “October Offering” or “Offering”) documents and other public statements omitted material facts regarding AbbVie’s interest in acquiring Cerevel at a price well in excess of the $22.81 per share Offering price, artificially deflating Cerevel’s stock price until the merger was announced. Moreover, Cerevel’s controlling shareholder, Bain Capital Investors, LLC (“Bain”), acquired Cerevel shares from the October Offering at an artificially depressed price while allegedly in possession of material nonpublic information regarding AbbVie’s interest. On December 6, 2023, Cerevel publicly announced that AbbVie agreed to acquire Cerevel for $45 per share. The merger allowed Bain to receive a windfall of more than $120 million on the shares it acquired at the artificially depressed Offering price. In addition, Cerevel’s January 18, 2024 Proxy statement misled investors regarding the true nature and timing of AbbVie’s interest in Cerevel.
In order to be included in the lawsuit, you must have sold shares during the class period listed above.
If you sold shares in Cerevel Therapeutics Holdings, Inc. during the relevant time frame , you have until June 03, 2025 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
TOP
